Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
February 26, 2021 08:33 ET
|
Revive Therapeutics Ltd.
TORONTO, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Revive Therapeutics Acquires Unique Psilocybin Assets
February 17, 2021 09:00 ET
|
Revive Therapeutics Ltd.
TORONTO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Revive Therapeutics Announces Closing of $23.0 Million Short Form Prospectus Offering
February 12, 2021 09:42 ET
|
Revive Therapeutics Ltd.
TORONTO, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV) (USA: RVVTF), a specialty life sciences company focused on the research and development of...
Revive Therapeutics Provides Update on Cannabinoid Pharmaceuticals Program
February 11, 2021 07:28 ET
|
Revive Therapeutics Ltd.
TORONTO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Revive Therapeutics Receives Receipt for Final Short-Form Prospectus for Previously Announced $20 Million Bought Deal Public Offering
February 09, 2021 17:00 ET
|
Revive Therapeutics Ltd.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV) (USA:...
Revive Therapeutics Files Business Acquisition Report
February 08, 2021 17:39 ET
|
Revive Therapeutics Ltd.
TORONTO, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV) (USA: RVVTF), announces that it has filed a Form 51-102F4 Business Acquisition Report (BAR)...
Revive Therapeutics Included in First Psychedelic Exchange Traded Fund
January 22, 2021 11:05 ET
|
Revive Therapeutics Ltd.
TORONTO, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Revive Therapeutics Announces Research Collaboration with North Carolina State University for Natural Biosynthesis Enzymatic Platform To Develop Psilocybin
January 14, 2021 07:00 ET
|
Revive Therapeutics Ltd.
TORONTO, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Dr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 Study
December 31, 2020 07:00 ET
|
Revive Therapeutics Ltd.
TORONTO, Dec. 31, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Plans on Emergency Use Access
December 23, 2020 08:55 ET
|
Revive Therapeutics Ltd.
TORONTO, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...